"This transaction reflects our continued commitment to unlocking shareholder value through the strategic development and monetization of our subsidiaries," said Jason Grady, CEO of DSS, Inc. "We believe the combination of Impact's disruptive pipeline with Dr. Ashleys' global infrastructure and commercial expertise will establish a robust, scalable biopharmaceutical platform. It further validates our strategy of creating long- term value by preparing our key assets for public market growth." NEW YORK, June 2 ...

Regina, Saskatchewan--(Newsfile Corp. - June 12, 2025) - Above Food Ingredients Inc. (NASDAQ: ABVE) ("the Company"), is pleased to announce it has received the official compliance determination letter from NASDAQ confirming that the Company now meets full compliance and has satisfied all of the requirements under Listing Rules 5450(b)(3)(C), 5810(c)(3)(A) and 5450(a)(1).As referenced within our press release dated June 6, the Company regained compliance with listing Rule 5450(b)(3)(C), regarding the minimu ...